Matthew N. Wakeling
ORCID: 0000-0002-6542-9241Also affiliated with Royal Devon & Exeter NHS Foundation Trust, NIHR Exeter Clinical Research Facility, Genomics (United Kingdom)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “REVEL Is Better at Predicting Pathogenicity of Loss-of-Function than Gain-of-Function Variants”.
Matthew N. Wakeling, Matthew B. Johnson, Sarah E. Flanagan, Thomas W. Laver, Jasmin J. Hopkins
Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
Masato Ogishi, Clara Domingo‐Vila, Elisa De Franco, Matthew N. Wakeling, Zineb Imane +22 more
Senthil Senniappan, Thomas W. Laver, Richard Caswell, Martin Zenker, Klaus Mohnike +17 more
Yiying Cai, Bernice Lo, Guy Helman, Henry M. Taylor, Amber J. McCartney +40 more
Nick Owens, Hossam Montaser, Matthew N. Wakeling, Jonna Saarimäki‐Vire, Athina Triantou +34 more